Although autologous therapies offer great advantages in terms of host compatibility, their manufacturing presents challenges along several parameters, including control strategy and supply chain. Allogeneic therapies, on the other hand, offer an opportunity to streamline therapy manufacturing for "off-the-shelf" supply, especially in case of emergency treatments. In this edition of Experts' Insights in Advanced Therapies, Kim Nguyen, Vice President of CMC at Precision Biosciences describes the company’s strategy in streamlining allogeneic CAR-T therapy manufacturing.
The Expert:
Kim Nguyen
Vice President CMC
Precision Biosciences
Kim is part of the Cell Therapy team at Precision Biosciences focused on the process development, analytics, and manufacturing of allogeneic CAR T-cell products. Before joining Precision Biosciences, she served as Principal Scientist and Senior Manager for Strategic Initiatives at Terumo BCT. Kim received her AB from Princeton University and her Ph.D. from Columbia University, both in Chemistry.
